研發開支大增138.6% 康哲藥業(00867.HK)中期純利升11.4%至13億元 中期息0.2105元
格隆匯8月12日丨康哲藥業(00867.HK)公佈，截至2020年6月30日止6個月，公司營業額增長4.8%至人民幣31.08億元，毛利增長3.4%至人民幣22.93億元，期間溢利增長11.4%至人民幣13億元，每股基本盈利人民幣0.5174元，宣派中期股息每股人民幣0.2105元，較去年同期增長11.8%。
於報告期內，集團在創新管線擴展、創新產品註冊及臨牀推進等方面取得重大進展。期間創新管線持續擴展，獲得創新產品PLENITY在中國大陸、港、澳、台及新加坡、阿拉伯聯合酋長國的獨家許可權利。PLENITY為美國FDA批准的由天然來源材料製成的安全有效的口服體重管理產品。獲得創新產品德度司他（Desidustat）在中國大陸、港、澳、台的獨家許可權利。德度司他為受專利保護的新分子實體，用於治療慢性腎病患者的貧血。
期間創新產品在中國註冊及臨牀工作取得積極進展，創新產品地西泮鼻噴霧劑在健康受試者體內的比較PK研究相關試驗工作已展開，並獲得研究中心倫理批件。創新產品0.09%環孢素滴眼液獲得中國NMPA簽發的臨牀試驗通知書，同意開展產品治療乾燥性角膜結膜炎的安全性和有效性的隨機、雙盲、安慰劑對照、多中心臨牀研究。?創新產品替拉珠單抗注射液（Tildrakizumab）的臨牀試驗申請獲得中國NMPA受理。現有業務穩健發展。
期間公司在售核心產品線錄得穩健增長。專業、合規、高效的推廣體系通過數字化賦能，運營效率進一步提升。推廣網絡持續擴展與細化，於報告期內，集團推廣網絡已覆蓋全國約57,000家醫院及醫療機構。
報告期內，集團研發開支總額增加138.6%，達到人民幣3.66億元；研發開支總額佔營業額比率為11.8%，較去年同期的5.2%增加6.6個百分點。若將兩票制收入還原則集團報告期研發開支總額佔營業額比率為10.3%，較去年同期的4.5%增加5.8個百分點，主要反映新產品管線的擴充和新產品研發活動的增加。
於2020年6月30日，集團銀行結餘及現金為人民幣21.09億元，可隨時變現的銀行承兑匯票為人民幣3.156億元。
未來發展：集團緊緊抓住醫藥產業鏈中兩大核心價值–產品力和推廣力。集團將繼續利用全球廣泛資源不斷擴充創新管線，並在中國實現藥物進一步開發及商業化，以提升產品力。同時不斷提升專業、合規、高效的推廣體系，為集團帶來可持續的、穩健的成長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
